PT - JOURNAL ARTICLE AU - Andrei R. Akhmetzhanov AU - Kenji Mizumoto AU - Sung-mok Jung AU - Natalie M. Linton AU - Ryosuke Omori AU - Hiroshi Nishiura TI - Estimation of the actual incidence of coronavirus disease (COVID-19) in emergent hotspots: The example of Hokkaido, Japan during February–March 2020 AID - 10.1101/2020.04.24.20077800 DP - 2020 Jan 01 TA - medRxiv PG - 2020.04.24.20077800 4099 - http://medrxiv.org/content/early/2020/05/04/2020.04.24.20077800.short 4100 - http://medrxiv.org/content/early/2020/05/04/2020.04.24.20077800.full AB - Following the first report of coronavirus disease 2019 (COVID-19) in Sapporo City, Hokkaido Prefecture, Japan on 14 February 2020, a surge of cases was observed in Hokkaido during February and March. As of 6 March, 90 cases were diagnosed in Hokkaido. Unfortunately, many infected persons may not have been recognized as cases due to having mild or no symptoms. We therefore estimated the actual number of COVID-19 cases in (i) Hokkaido Prefecture and (ii) Sapporo City using data on cases diagnosed outside these areas. The estimated cumulative incidence in Hokkaido as of 27 February was 2297 cases (95% confidence interval [CI]: 382, 7091) based on data on travelers outbound from Hokkaido. The cumulative incidence in Sapporo City as of 28 February was estimated at 2233 cases (95% CI: 0, 4893) based on the count of confirmed cases within Hokkaido. Both approaches resulted in similar estimates, indicating higher incidence of infections in Hokkaido than were detected by the surveillance system. This quantification of the gap between detected and estimated cases can help inform public health response as it provides insight into the possible scope of undetected transmission.Competing Interest StatementThe authors have declared no competing interest.Funding StatementH.N. received funding from the Japan Agency for Medical Research and Development (AMED) [grant number: JP18fk0108050]; the Japan Society for the Promotion of Science (JSPS) KAKENHI [grant numbers: 17H04701, 17H05808, 18H04895 and 19H01074], the Inamori Foundation, and the Japan Science and Technology Agency (JST) CREST program [grant number: JPMJCR1413]. K.M. acknowledges support from the JSPS KAKENHI [grant no. 15K20936], the Program for Advancing Strategic International Networks to Accelerate the Circulation of Talented Researchers (grant no. G2801), and the Leading Initiative for Excellent Young Researchers from the Ministry of Education, Culture, Sport, Science, and Technology of Japan. S-m.J. and N.M.L. receive graduate study scholarships from the Ministry of Education, Culture, Sports, Science and Technology, Japan.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData on COVID-19 confirmed cases, including dates of illness onset, subprefecture of diagnosis, travel history to Sapporo, and epidemiologic linkage to other confirmed cases were retrieved from the websites of government entities in Hokkaido. http://github.com/aakhmetz/Covid19IncidenceHokkaidoFeb2020